[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ART Fertility Clinics LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":508},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,48,80,98,124,160,184,211,243,267,286,308,329,353,377,410,438,457,484],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100594040","virtual-reality-for-mindfulness-and-anxiety-reduction-in-fertility-procedures-100594040",false,"NCT07014267","Virtual Reality for Mindfulness and Anxiety Reduction in Fertility Procedures","Inclusion Criteria:\n\n* Patients aged 18-50.\n* Scheduled for fertility-related surgical procedures.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* History of motion sickness or VR-related discomfort.\n* Cognitive or psychological conditions affecting participation.\n* Procedures requiring emergency intervention.",true,"ALL","18 Years","50 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the effectiveness of a Virtual Reality (VR)-based mindfulness and meditation intervention in reducing anxiety among patients undergoing fertility-related surgical procedures. Anxiety is a common challenge in fertility treatments, often leading to emotional distress and increased pain perception. By incorporating a non-invasive VR intervention, the investigators seek to improve patient experience, minimize preoperative anxiety, and potentially reduce postoperative discomfort and recovery times. This randomized controlled trial (RCT) will compare standard care with a VR intervention in a clinical setting, measuring key outcomes such as anxiety levels, pain perception, recovery duration, and overall patient satisfaction. The findings may contribute to more patient centered fertility care, offering an innovative, scalable, and cost-effective approach to anxiety management in reproductive medicine.",[27,28],"Virtual Reality","Patient Experience",[30,31,32,33,34],"anxiety","stress","pain perception","recovery duration","virtual reality","RECRUITING","2026-06-22",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":39},"2025-07-10",{"date":43,"type":21},"2026-12-31",{"name":45,"class":46},"ART Fertility Clinics LLC","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":15,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":78,"locationsCount":79},"100586047","whole-brain-dynamics-in-the-natural-menstrual-cycle-vs-an-ovarian-stimulated-cycle-impact-of-hormonal-fluctuations-on-healthy-women-undergoing-ovarian-stimulation-100586047","NCT06910293","Whole-Brain Dynamics in the Natural Menstrual Cycle vs. an Ovarian Stimulated Cycle: Impact of Hormonal Fluctuations on Healthy Women Undergoing Ovarian Stimulation","Inclusion Criteria:\n\n* Age group: 25 - 35 years old\n* BMI: 20 - 30\n* Anti-Mullerian Hormone (AMH): 1.3 - 5.9 ng\u002Fml\n* Regular Menstrual Cycle: 26-35 days\n* In case of previous use of hormonal contraception: wash-out period of 3 month\n* Meet standard safety and eligibility criteria for MRI scanning, including the absence of contraindications such as metallic implants, claustrophobia, or other medical conditions that preclude MRI\n\nExclusion Criteria:\n\n* History of ovarian surgery\n* Pathology of the ovaries\n* Mental health disorders\n* Use of medication influencing brain function\n* Ongoing use of hormonal contraception (this would include OCP, but also patches and Mirena containing IUD)","FEMALE","25 Years","35 Years",{"count":58,"type":21},15,"8 Weeks","OBSERVATIONAL","The investigators aim is to investigate the brain's dynamic complexity across three phases of an ovarian stimulation cycle (basal, pre-OPU, mid-luteal), to observe the impact of externally administered hormones, and compare it with the corresponding phases of a natural menstrual cycle (early follicular, pre-ovulatory, mid-luteal) in the same woman. Brain activity patterns will be examined using resting-state fMRI in a sample of young, healthy, naturally cycling women.",[63,64,65,66],"Neural Activity","Brain Function","Neurodynamics","Brain Connectivity",[68,69,70,71,72],"Menstrual Cycle","Ovarian Stimulated Cycle","Endocrine Profile","neural activity","neurodynamics",{"date":74,"type":39},"2026-06-23",{"date":76,"type":39},"2025-04-07",{"date":43,"type":21},{"name":45,"class":46},2,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":89,"studyType":60,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":97,"locationsCount":47},"100580590","follicular-volume-at-the-time-of-final-oocyte-maturation-in-poor-responders-and-its-correlation-with-oocyte-maturity-100580590","NCT06839274","Follicular Volume at the Time of Final Oocyte Maturation in Poor Responders, and Its Correlation With Oocyte Maturity","Inclusion Criteria:\n\n* Reproductive age group: 18 -48\n* undergoing ovarian stimulation for oocyte vetrification\n* undergoing IVF\u002F ICSI with PGT-A \u002F PGT-M \u002F PGT- Sr\n* less than or equal to 3 AFC on initiation of stimulation\n* follicular phase stimulation\n\nExclusion Criteria:\n\n* surgically retrieved sperm","48 Years",{"count":88,"type":21},100,"30 Months","Women with a severely diminished ovarian reserve and monofollicular growth are at a higher risk of premature ovulation as well as poor quality oocytes. Our group showed previously that women with severely diminished ovarian reserve benefit from receiving the final oocyte maturation at smaller follicle sizes in terms of reducing the risk of premature ovulation and finding mature oocytes even out of small size follicles.\n\nAdding the measurement of the follicular volume at the time of final oocyte maturation might provide more information on the proper timing of trigger administration compared to the follicular size alone, hormonal profile as well as previous stimulation attempts. Setting a cutoff value of follicular volume for trigger might help to avoid premature ovulation and possibly increase the chances of ending up with a euploid embryo.",[92],"OVARIAN STIMULATION",{"date":38,"type":39},{"date":95,"type":39},"2025-03-27",{"date":43,"type":21},{"name":45,"class":46},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":109,"studyType":60,"phases":4,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":47},"100560114","serum-fsh-monitoring-for-identification-of-an-optimal-range-during-ovarian-stimulation-100560114","NCT06572930","Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation","Assessment of the Role of Serum FSH Monitoring During Ovarian Stimulation and Identification of an Optimal Range for Expected Normal Responders","FSH","Inclusion Criteria:\n\n* regular 21 - 35 days cycles\n* BMI between 19 - 30 kg\u002Fm2\n* serum AMH level between 1.5 to 3 ng\u002Fml\n* a total antral follicle count between 10 to 24\n* endogenous early follicular phase serum FSH level \\\u003C10 IU\u002FL\n* normal glomerular filtration rate\n\nExclusion Criteria:\n\n* hypogonadotropic hypogonadism\n* history of ovarian surgery\n* permanent ovarian cysts of any form\n* older than 39 years\n* abnormal thyroid stimulating hormone (TSH)\n* renal disease\n* elevated prolactin levels\n* intake of oral contraceptives 3 months before stimulation start and estradiol pretreatment will be excluded","39 Years",{"count":108,"type":21},150,"1 Year","This study examines if monitoring serum Follicle Stimulation Hormone (FSH) levels can predict oocyte yield and progesterone levels, considering factors like age, baseline FSH, Antral Mullerian Hormone (AMH), antral follicle count, body weight, kidney function, and urinary FSH. The aim is to find a minimum FSH level that ensures optimal ovarian response and enables tailored FSH dosages for better outcomes.",[112],"Ovarian Stimulation",[114,115,116,117],"ovarian response","stimulation protocols","stimulation monitoring","follicular stimulating hormone",{"date":38,"type":39},{"date":120,"type":39},"2024-12-16",{"date":122,"type":21},"2026-12-01",{"name":45,"class":46},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":144,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":159,"locationsCount":47},"100528791","hyaluronan-enriched-medium-and-euploid-blastocyst-transfers-100528791","NCT06165367","Hyaluronan-enriched Medium and Euploid Blastocyst Transfers","Impact of Hyaluronan-enriched Medium on Pregnancy Outcomes Following Euploid Blastocyst Transfers","GluePloid","Inclusion Criteria:\n\n* All frozen embryo transfer (FET) cycles with euploid blastocysts biopsied and vitrified on Day 5 after PGT-A.\n* Rank of randomization based on embryo quality.\n* Only hormonal replacement theraphy (HRT) cycle regimen.\n* Women aged 18 years to 46 years.\n* Having at least 1 chromosomally normal vitrified blastocyst(s) on Day 5 available for transfer.\n* All sperm samples.\n* BMI between 18 and 35.\n\nExclusion Criteria:\n\n* FET cycles with preimplantation genetic testing for monogenic disorders (PGT-M) and for structural rearrangements (PGT-SR).\n* FET cycles with mosaic \u002F aneuploid blastocysts.\n* FET cycles with unknown outcome.\n* FET cycles with Day 6 or Day 7 biopsied blastocysts.\n* FET with patients' endometrium preparation with treatments other than HRT.\n* FET where PGT-A was performed for gender selection.","46 Years",{"count":134,"type":21},783,[24],"It has been proposed that enriching transfer media with hyaluronan (EmbryoGlue medium) improves pregnancy outcomes compared with media containing lower concentrations of this molecule. However, none of previous studies included preimplantation genetic testing for aneuploidy (PGT-A) embryos. In order to investigate the impact of this hyaluronan-enriched on pregnancy outcomes, it is essential to evaluate its efficacy on euploid-only embryo transfers. The aim of the present study is to evaluate whether a short period of exposure of euploid blastocysts to EmbryoGlue prior to and during transfer positively impact on pregnancy outcomes of frozen embryo transfer (FET) cycles.",[138,139,140,141,142,143],"Infertility","Implantation Rate","Clinical Pregnancy Rate","Live Birth Rate","Blastocysts","FET",[145,146,147,148,149,150,151,152,153,154],"HRT","PGT-A","Next-generation sequencing (NGS)","Miscarriage rate","single embryo transfer (SET)","EmbryoGlue","BMI","Embryo quality","Hyaluronan-enriched medium","Transfer medium",{"date":38,"type":39},{"date":157,"type":39},"2024-01-15",{"date":43,"type":21},{"name":45,"class":46},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":54,"minAge":4,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":182,"locationsCount":183},"100513753","is-decreased-ovarian-reserve-related-to-an-increased-number-of-previous-early-miscarriages-100513753","NCT05969574","Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?","Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages? A Prospective Observational Study","Inclusion Criteria:\n\n1\\. All participants with at least 1 previous pregnancy, who are assessed in one of our clinics (ART Fertility Clinics Abu Dhabi, Al Ain, Dubai)\n\nExclusion Criteria:\n\n1. Severe male factor (azoospermia, cryptozoospermia, severe oligoasthenoteratozoospermia (OAT))\n2. Severe Endometriosis and adenomyosis based on positive anamnesis or ultrasound performed in our center during the first consultation\n3. Uterine abnormalities (e.g. fibroids, different degrees of uterine septum), diagnosed by ultrasound\n4. History of ovarian surgery, chemotherapy, or radiation therapy\n5. Known genetic disorder or chromosomal abnormality\n6. BMI \\>40Kg\u002Fm2\n7. Currently using hormonal contraception or hormone replacement therapy",{"count":168,"type":21},2059,"This study aims to explore the potential correlation between decreased ovarian reserve and previous history of early miscarriage.",[171,172,173,174],"Infertility, Female","Miscarriage","Miscarriage, Recurrent","IVF",[176,177,174],"miscarriage","infertility",{"date":38,"type":39},{"date":180,"type":39},"2023-09-09",{"date":43,"type":21},{"name":45,"class":46},3,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":47},"100475618","descriptive-analysis-of-serum-immunological-markers-during-an-euploid-frozen-embryo-transfer-in-a-natural-cycle-100475618","NCT05473273","Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle.","Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle (NC).","Inclusion Criteria:\n\n* Women aged 18 years to 40 years\n* Having at least one good quality (grade A or B for inner mass cell and trophectoderm) day 5 or 6 chromosomally normal cryopreserved blastocyst available for transfer\n* Single embryo transfer in a natural cycle (NC) or an Hormone Replacement Therapy (HRT) protocol\n* Fresh ejaculate used for fertilization\n\nExclusion Criteria:\n\n* Body mass index lower than 18.5 or equal or higher than 29 kg\u002Fm2\n* Endometriosis or adenomyosis suspected by medical history (dysmenorrhea, dyspareunia, heavy or prolonged menstrual bleeding (\\> 8 days), chronic pelvic pain, catamenial rectal or bladder symptoms) or diagnosed by imaging (magnetic resonance imaging or ultrasonography)\n* Uterine abnormalities\n* Hydrosalpinx\n* Insulin resistance or diabetes mellitus diagnosed by HbA1c 5.7 %\n* Antiphospholipid syndrome\n* Polycystic ovarian syndrome according to Rotterdam criteria: presence of at least two of the following: irregular cycles (\\\u003C 21 or \\> 35 days or \\\u003C 8 cycles a year), biochemical or clinical hyperandrogenism, ovarian ultrasound morphology (\\> 20 follicles per ovary on transvaginal scan) or Anti-mullerian hormone \\> 5,98 ng\u002Fml\n* History of recurrent miscarriage, defined as the loss of 2 or more pregnancies according to ESHRE guidelines\n* History of implantation failure, considered as the lack of pregnancy after the transfer of 2 good-quality (grade A or B for inner mass cell and trophectoderm (29)) euploid embryos\n* History or suspicion of Asherman syndrome\n* Autoimmune disease\n* Couple first degree consanguineous","40 Years",{"count":193,"type":21},40,"To describe the peripheral serum levels of the anti-inflammatory cytokines IL-4 (Interleukin-4), IL-10 (Interleukin-10), TGF-ß1 (Transforming Growth Factor beta1), the pro-inflammatory cytokines IL-17 (Interleukin-17), IFγ (Interferon Gamma) and the immune mediator PIBF (Progesterone-Induced Blocking Factor) along a single frozen euploid blastocyst transfer in a natural cycle (NC) or Hormone Replacement Therapy (HRT).",[171],[197,198,199,200,201,202,203,204],"infertilty","ivf","progesterone","estradiol","cytokines","immunology","Pharmacological effect of drugs","hormones",{"date":38,"type":39},{"date":207,"type":39},"2023-04-24",{"date":209,"type":21},"2026-12-30",{"name":45,"class":46},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":227,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":242,"locationsCount":4},"100636796","comparison-of-two-types-of-calcium-ca-ionophore-treatments-for-oocyte-activation-in-cases-of-suboptimal-fertilization-potential-100636796","NCT07570342","Comparison of Two Types of Calcium (Ca²⁺) Ionophore Treatments for Oocyte Activation in Cases of Suboptimal Fertilization Potential","(Ca²⁺)","Inclusion Criteria:\n\n1. Patients undergoing assisted reproductive technology cycles when ICSI is indicated.\n2. Patients with a minimum of 3 MII oocytes after denudation.\n3. Maternal age 18-43 years old.\n4. PGT-A cycles with only trophectoderm biopsies on day 5\u002F6\u002F7.\n5. BMI\\\u003C35.\n6. Fresh and frozen immotile ejaculated sperm.\n7. Fresh and frozen TESE sperm (motile and immotile).\n8. Globozoospermia.\n\n10\\. Couples undergoing ICSI due to poor fertilization history (≤30%), or previous fertilization failure.\n\nExclusion Criteria:\n\n1. PGT-M\u002FSR cycles.\n2. Fresh and frozen motile ejaculated \u002F FNA sperm.\n3. IVF inseminated oocytes.","43 Years",{"count":220,"type":21},20,[24],"This study aims to investigate the effectiveness and safety of assisted oocyte activation (AOA) using Ca²⁺ ionophores in cases of total fertilization failure (TFF) due to oocyte activation deficiency (OAD). The study will be conducted in two phases: Phase I will compare the fertilization rates of oocytes exposed to two types of Ca²⁺ ionophore treatments- Ionomycin solution and commercially available CultActive-against a control group without calcium ionophore treatment. Phase II will assess whether an additional injection of CaCl2, prior to exposure to the chosen ionophore from Phase I, further improves fertilization outcomes. The goal is to identify the optimal AOA protocol for improving fertilization rates and to evaluate the safety and efficacy of this approach in relation to ploidy, with a focus on ensuring normal pre-implantation embryo development.",[224,225,226,146],"ICSI","Testicular Sperm Extraction in Azoospermic Patients","Male Infertility",[224,146,228,229,230,231,232,233,234],"artificial oocyte activation","AOA","calcium ionophore","ionomycin","TESE","Immotile sperm","Failed fertilization","NOT_YET_RECRUITING","2026-05-06",{"date":238,"type":39},"2026-05-11",{"date":240,"type":21},"2026-04-30",{"date":43,"type":21},{"name":45,"class":46},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":218,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":47},"100613719","impact-of-dry-vs-humidified-culture-conditions-on-blastocyst-development-and-aneuploidy-a-time-lapse-sibling-oocyte-study-100613719","NCT07270250","Impact of Dry vs Humidified Culture Conditions on Blastocyst Development and Aneuploidy: A Time-lapse Sibling Oocyte Study","Inclusion Criteria:\n\n* PGT-A cycles with more than at least 4 mature oocytes\n* ICSI\n* maternal age 18- 43 years old\n* PGT-A intended cycles with trophectoderm biopsies on day 5 \u002F6\u002F7\n* patients with more than 8 oocytes expected for ICSI\n* BMI \\\u003C35\n* fresh and frozen ejaculated sperm\n\nExclusion Criteria:\n\n* PGT-M \u002FPGT-SR cycles\n* fresh and frozen testicular sperm\n* IVF insemination\n* previous history of fertilization failure",{"count":250,"type":21},60,[24],"IVF incubators are essential for maintaining the micro-environment required for embryo development. Incubator technology has progressed from early humidified box systems to benchtop and now time-lapse platforms, driving the development of dry incubator chambers. Both humidified and dry systems have specific pros and cons. Evidence to date suggests that humidified chambers may support better blastocyst development in certain \"no-refresh\" continuous culture conditions, but current data are limited and study designs remain weak. This study aims to compare sibling oocytes cultured in dry versus humidified chambers within a GERI time-lapse incubator under continuous culture conditions, assessing effects on viability and developmental outcomes. Findings may inform optimal incubation strategies to improve IVF success rates while supporting uninterrupted workflows and potentially improving cost-benefit efficiency in the IVF laboratory.",[254,255,256,257,258,259,224],"Incubator Stay","Total Blastulation","Blastocyst Quality","Biopsy Rate","Fertilization Rate","Ploidy Rate",{"date":261,"type":39},"2026-05-07",{"date":263,"type":39},"2026-02-10",{"date":265,"type":21},"2027-12-31",{"name":45,"class":46},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":56,"enrollmentInfo":273,"targetDuration":274,"studyType":60,"phases":4,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":284,"leadSponsor":285,"locationsCount":47},"100583523","is-the-diurnal-variation-in-circulating-levels-of-cortisol-reflected-in-follicular-fluid-of-preovulatory-follicles-close-to-ovulation-100583523","NCT06877429","Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?","Inclusion Criteria:\n\n* Indication for IVF \u002F ICSI - treatment\n\n  * Age ≥ 18 years and ≤ 35 years\n  * Body weight: 19 - 29 kg\u002Fm2\n  * Ovarian reserve parameters in the adequate age - range, determined by Anti-Muellerian-Hormone (AMH) and Antral Follicle Count (AFC) (Shebl 2011, Hamdine 2015)\n  * Regular cycle (25-35 days)\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years and \\> 35 years\n\n  * Body weight \\\u003C 60 kg and \\> 90 kg\n  * Ovarian reserve parameters outside the adequate age - range, determined by Anti-Muellerian-Hormone (AMH) and Antral Follicle Count (AFC) (Shebl 2011, Hamdine 2015)\n  * Proven poor responder in preceding IVF-treatment-cycle, according to the Bologna criteria: at least two of the following three features must be present:\n\n    (i) Advanced maternal age (≥40 years) or any other risk factor for POR (poor ovarian response) (ii) A previous POR (≤3 oocytes with a conventional stimulation protocol) (iii) An abnormal ovarian reserve test (i.e. AFC \\\u003C 5-7 follicles or AMH \\\u003C 0.5 -1.1 ng\u002Fml)\n  * Two episodes of POR after maximal stimulation are sufficient to define a patient as a poor responder in the absence of advanced maternal age or abnormal ORT\n  * Diagnosis of polycystic ovarian syndrome (PCOS), according to Rotterdam criteria\n  * Endometriosis stage 3 or 4 AFS (American Fertility Society)\n  * Irregular cycle (\\\u003C 25 days and \\> 35 days)\n  * Treatment with GnRH-analogues during the previous 6 months\n  * Intake of contraceptive pill (OCP) or any hormonal treatment during the last 3 months",{"count":220,"type":21},"6 Weeks","Glucocorticoids and especially cortisol exhibit a pronounced diurnal variation. Levels peak around 8 am and may decrease around two to three times during the day reaching a nadir during the evening and early in the night.\n\nOvulation has been described as a controlled inflammatory event. Following release of the oocyte, termination of the inflammatory reaction needs to take place in order for the follicle and the developing corpus luteum to avoid further damage. It has been suggested, that locally enhanced cortisol availability may play a role in limiting tissue damage and by acting as anti-inflammatory agents mediating repair and remodeling. The aim of the present study is evaluate the concentration of cortisol and cortisone in sets of serum and follicular fluid samples collected simultaneous and at different times of the day (8.00 a.m. and 8.00 p.m.) and compare the levels with the time of the day at which they are collected.",[277],"Healthy",[279,280,281],"ovarian stimulation","cortisol","cortisone",{"date":261,"type":39},{"date":209,"type":21},{"date":265,"type":21},{"name":45,"class":46},{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":293,"enrollmentInfo":294,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":296,"conditions":297,"keywords":300,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":305,"leadSponsor":307,"locationsCount":79},"100583644","comparing-ivficsi-cycle-outcomes-of-post-ovulation-ovarian-stimulation-protocol-with-elonva-without-gnrh-antagonist-to-follicular-phase-day-2-stimulation-fixed-day-5-antagonist-protocol-100583644","NCT06879002","Comparing IVF\u002FICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol","To Compare IVF\u002FICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Fixed Day 5 Antagonist Protocol","Inclusion Criteria:\n\n* Age 18 to 38 years old.\n* Normal Menstrual cycle of 25-35 days.\n* Body Weight 60to90 kg\n* AMH\\>1.3 - \\\u003C3 ng\u002Fm (Ferraretti and Gianaroli, 2014; Calzada et al., 2019) an antral follicle count (AFC) of \\>5 on menstrual cycle days 2-3,\n\nExclusion Criteria:\n\n* History of premature ovulation\n* Azoospermia\n* PCOS\n* Endometriosis AFS ¾\n* Endometrioma\n* Known chromosomal abnormalities","38 Years",{"count":295,"type":21},252,"There are several approaches to the timing of antagonist administration in IVF\u002FICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs \u002Fburden without having an impact on the outcome.",[298,299],"Stimulation in the Ovary","IVF Outcome",[199,301,279,302],"premature ovulation","luteal stimulation",{"date":261,"type":39},{"date":209,"type":21},{"date":306,"type":21},"2027-12-30",{"name":45,"class":46},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":56,"enrollmentInfo":314,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":328,"locationsCount":47},"100556547","relaxin-measurement-in-different-endometrial-preparation-approaches-for-frozen-embryo-transfer-100556547","NCT06526520","Relaxin Measurement in Different Endometrial Preparation Approaches for Frozen Embryo Transfer","Inclusion Criteria:\n\n* regular menstrual cycles\n\nExclusion Criteria:\n\n* abnormal findings of the ovaries (e.g endometriosis)\n* Intake of any hormones within 3 months of study start\n* desire to become pregnant",{"count":315,"type":21},5,"To investigate the levels of Relaxin in different types of endometrial preparation for a frozen embryo transfer cycle. Up to now it is unclear, whether ovulation with a functional corpus luteum (CL) will be present in a natural proliferative phase (NPP) endometrial preparation approach.",[318],"Frozen Embryo Transfer",[320,321,322,323],"frozen embryo transfer","hormonal replacement cycle","natural cycle","Relaxin",{"date":238,"type":39},{"date":326,"type":39},"2024-08-01",{"date":43,"type":21},{"name":45,"class":46},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":352,"locationsCount":47},"100600140","evaluating-the-utility-of-implementing-microfluids-for-sperm-preparation-compared-to-conventional-method-of-density-gradient-centrifugation-in-a-pgt-a-program-a-sibling-oocyte-study-100600140","NCT07093619","Evaluating the Utility of Implementing Microfluids for Sperm Preparation Compared to Conventional Method of Density Gradient Centrifugation in a PGT-A Program: a Sibling Oocyte Study","Inclusion Criteria:\n\n1. Women with at least 8 MII per cycle after denudation (AFC≥8).\n2. Women of all ages.\n3. All embryo qualities ≥BL3CC at the time of biopsy on day 5, 6 and\u002For 7.\n4. Fresh sperm used from ejaculate with a concentration ≥1 mill\u002Fml and ≥10% motility (A+B).\n5. Sperm samples with a minimum of 2 ml.\n\nExclusion Criteria:\n\n* Frozen oocytes samples with severe oligospermia (≤1mill\u002Fml).\n* PGT-M cases\n* Sperm with \\> 1M\u002Fml of round cells",{"count":88,"type":21},[24],"In assisted reproductive technology (ART), sperm preparation aims to select the most viable sperm for ICSI. Unlike conventional methods like density gradients or sperm washing, microfluidic techniques mimic natural selection in the female reproductive tract by using laminar flow without centrifugation, reducing the risk of DNA damage. This method isolates highly motile sperm while filtering out debris and immotile cells. Studies show that microfluidics improve embryo quality, increase pregnancy rates, and may lead to higher euploidy rates. Additional benefits include improved safety, scalability, and shorter preparation times.",[339,224,146],"Semen Analysis",[174,341,342,343,344,345],"Sperm Preparation","euploid","fertilization rate","blastulation rate","morphokinetics","2025-09-30",{"date":348,"type":39},"2025-10-02",{"date":350,"type":39},"2025-09-12",{"date":209,"type":21},{"name":45,"class":46},{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":191,"enrollmentInfo":360,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":376,"locationsCount":47},"100503597","is-the-amh-intrafollicular-level-a-predictor-of-the-ploidy-status-of-the-blastocyst-100503597","NCT05837325","Is the AMH Intrafollicular Level a Predictor of the Ploidy Status of the Blastocyst?","Is the AMH Intrafollicular Level a Predictor of the Ploidy Status of the Blastocyst? A Prospective Study","Inclusion Criteria:\n\n* At least one follicle from each ovary at day of trigger\n* Age from 18 to 40 years old\n* Normal menstrual cycle of 25-35 days\n* Poor, normal and high response will be included\n* First follicle punctured from each ovary will be consider for inclusion: if the COC (Cumulus Oocyte Complex) is present in clear FF (Follicular fluid), the FF will be collected separately for further analysis and the oocyte included in the study\n\nExclusion Criteria:\n\n* Very hematic follicular fluid\n* If the COC is not found in the follicular fluid\n* Azoospermia\n* Known chromosomal abnormalities\n* Severe OAT (Oligoasthenoteratozoospermia)",{"count":361,"type":21},300,"To investigate, whether on the day of egg retrieval, after ovarian stimulation for ICSI (intracytoplasmic sperm injection), there is a correlation between the intrafollicular AMH (Anti-Müllerian hormone) levels and the ploidy status of the blastocyst.",[171,138],[365,104,366,367,368,369,138,370,371],"Estradiol","LH","AMH","Ploidy","Chromosomes","Progesterone","Inhibin B",{"date":348,"type":39},{"date":374,"type":39},"2023-05-23",{"date":43,"type":21},{"name":45,"class":46},{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":293,"enrollmentInfo":384,"targetDuration":386,"studyType":60,"phases":4,"briefSummary":387,"conditions":388,"keywords":391,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":47},"100572405","does-recombinant-fsh-rfsh-ig-gonal-f-as-compared-to-human-menopausal-gonadotrophin-hmg-affect-telomere-length-of-cumulus-cells-during-antral-follicle-growth-and-impact-blastocyst-status-100572405","NCT06732843","Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?","rFSH and hMG","Inclusion Criteria:\n\n1. Maternal age 18 - 38 years\n2. Patients requested PGT-A\n3. BMI 18- 30kg\u002Fm2\n4. Expected normoresponders\n5. Fresh autologous ejaculate (≥5 mill\u002Fml)\n6. Sperm abstinence: 2-3 days\n7. Normal female\u002Fmale karyotype\n8. Regular menstrual cycle length: 25-32 days\n9. AFC of 5-10 in each ovary at the beginning of the stimulation\n10. Trigger: dual trigger: 2.500 IU urinary hCG + 0.3 mg Decapeptyl. (13)\n11. A wash-out period between 1 to 3 months; an inter-cycle variation of 10% in AFC, measured by the same physician, is accepted.\n12. Couple agrees to perform two stimulations before continuing with embryo transfer\n\nExclusion Criteria:\n\n* 1\\. Uterine abnormalities as diagnosed by ultrasound 2. Any hormonal or oral contraceptive pretreatment of 3 months preceding the treatment 3. Endometriosis according to American Fertility Society (AFS) ≥3 4. ≥ 2 miscarriages 5. Bologna criteria poor responders (14)",{"count":385,"type":21},10,"60 Months","Gonal-F® (follitropin alfa) is a recombinant FSH without LH activity, while Menopur® contains both LH and hCG. The MEGASET trial compared Menopur® and Gonal-F® in GnRH antagonist cycles with SET, showing similar efficacy. A subsequent study (MEGASET-HR) in high responders found ongoing pregnancy rates of 35.5% for Menopur® and 30.7% for Gonal-F®, with a lower early pregnancy loss for Menopur® (14.5% vs 25.5%).\n\nTelomere length (TL) in oocyte cumulus cells (CC) correlates with oocyte quality and embryo outcomes. This study aims to assess whether stimulation type (hMG vs. Gonal-F) affects TL in CC and subsequent blastocyst development. A randomized, open-label, cross-over study in normo-responders will analyze telomere length, embryo quality, and hormonal markers.",[92,389,390],"Telomere Length","Telomere Length, Mean Leukocyte",[392,393,394,395,396,397,398,399,400,401],"recombinant human follicle-stimulating hormone (rFSH)","uman-menopausal-gonadotropin (hMG","ocyte quality","embryo quality","blastocyst development","Menopur","GonalF","GnRH antagonist cycles","trophectoderm","cumulus cells","2025-07-24",{"date":404,"type":39},"2025-07-25",{"date":406,"type":39},"2025-07-23",{"date":408,"type":21},"2027-07-31",{"name":45,"class":46},{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":419,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":47},"100536195","effect-of-antioxydant-enriched-media-on-blastocyst-euploidy-rates-100536195","NCT06261671","Effect of Antioxydant-enriched Media on Blastocyst Euploidy Rates.","Antioxidants-enriched Single-step vs Global Total Single-step Embryo Culture Media: Effect on Blastocyst Euploidy Rates.","GX","Inclusion Criteria:\n\n* Patients undergoing assisted reproductive technology cycles when ICSI is indicated.\n* Patients when Iin vitto fertilization (IVF) is also performed will be included as far as there are enough oocytes for ICSI randomization. However, IVF oocytes will not be used for the study.\n* Maternal age 18-43 years old.\n* PGT-A cycles with only trophectoderm biopsies on day 5\u002F6\u002F7.\n* Patients with more than 6 COCs expected for ICSI.\n* Body mass index \\\u003C35.\n* Fresh and frozen ejaculated sperm.\n\nExclusion Criteria:\n\n* PGT-M cycles\n* Fresh and frozen testicular sperm.",{"count":20,"type":21},[24],"One of the most sensible factors in IVF culture conditions is the susceptibility of gametes and embryos to an induced increase in reactive oxidative species (ROS) caused by the artificial environment. This study aims to evaluate the impact of using antioxidant-supplemented media during culture to evaluate embryo ploidy rates in a prospective randomized trial using sibling oocytes.",[138,422],"In Vitro Fertilization",[424,425,426,427,428,429],"Intracytoplasmic sperm injection","Pre - implanttaion genetic diagnosis for aneuploidy","Antioxydante","Culture media","Embryo development","Euploidy","2025-02-20",{"date":432,"type":39},"2025-02-21",{"date":434,"type":39},"2024-02-01",{"date":436,"type":21},"2025-12-31",{"name":45,"class":46},{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":191,"enrollmentInfo":445,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":456,"locationsCount":47},"100392462","is-there-a-role-for-mechanical-stimulation-in-ovarian-follicular-activation-100392462","NCT04390308","Is There A Role For Mechanical Stimulation In Ovarian Follicular Activation?","Is There A Role For Mechanical Stimulation In Ovarian Follicular Activation? A Randomized Control Trial.","Inclusion Criteria:\n\n* Signed and dated informed consent\n* Women 40 years of age and younger with documented primary ovarian insufficiency (12).\n* Normal Karyotype\n* BMI \\\u003C\u002F= 35 kg\u002Fm2\n* Oligo\u002Famenorrhea for at least 4 months\n* FSH \\> 25 IU\u002FmL\n* AMH \\\u003C\u002F= 0,1 ng\u002Fml\n* No evidence of follicles \\> 4mm\n* Must have two ovaries of approximately equal volume.\n* Willingness to undergo further fertility treatment, including IVF if there is evidence of response\n* A transvaginal scan including Doppler for arteria ovarica will be performed previously to the surgical procedure.\n\nExclusion Criteria:\n\n* Premature ovarian failure due to a genetic origin, such as Turner's Syndrome or chromosomal abnormality.\n* Oncological diseases (specially, skeletal system and blood).\n* Autoimmune diseases, for example, lupus erythematosus, etc.\n* Previous treatments including radiotherapy or chemotherapy.\n* Other conditions not suitable for surgical procedures and\u002For anesthesia.\n* Anticoagulant or antiaggregant treatment.\n* Acute and chronic infectious diseases.\n* Active substance abuse or dependence.\n* Major Mental health disorder.",{"count":446,"type":21},70,"Premature ovarian failure (POI) is a loss of normal function before age 40, leading to infertility and hypoestrogenism. About 1% of women younger than 40 years old and 0.1% before 30 are affected. Most patients already had impaired or complete loss of fecundity when diagnosed. Hence, the treatment of POI is particularly tough. Currently, no optimal regimen exists to ameliorate ovarian function.",[171,449,174],"Premature Ovarian Failure","2025-02-17",{"date":452,"type":39},"2025-02-19",{"date":454,"type":39},"2021-06-02",{"date":436,"type":21},{"name":45,"class":46},{"id":458,"slug":459,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":15,"sex":54,"minAge":17,"maxAge":191,"enrollmentInfo":464,"targetDuration":4,"studyType":22,"phases":466,"briefSummary":468,"conditions":469,"keywords":471,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":183},"100513770","phase-1-comparison-of-live-birth-rate-in-natural-cycle-single-euploid-fet-versus-without-luteal-phase-support-100513770","NCT05969795","Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support","Comparison of Live Birth Rate (> 24 Weeks) in Natural Cycle (NC) Single Euploid Frozen Embryo Transfers (FET) With Versus Without Luteal Phase Support (LPS)","Inclusion Criteria:\n\n* Age: 18 to 40 years\n* Regular ovulatory cycles\n* Availability of at least one euploid embryo after Trophectoderm biopsy for PGT-A on day 5 or day 6\n* Detection of ovulation by P4 rise \\> 1.0 ng\u002Fml after LH surge\n* P4 value of at least 5 ng\u002Fml on day 4 after ovulation\n\nExclusion Criteria:\n\n* History of repeated pre-menstrual spotting\n* Factors affecting the implantation through anatomical changes of the uterus \u002F ovaries or the tubes (adenomyosis, Asherman syndrome, endometriosis, uterine fibroids \u002F polyps, isthmocele with intracavitary fluid presence, hydrosalpinx….)",{"count":465,"type":21},342,[467],"PHASE1","To evaluate whether single euploid embryo transfer in NC without routinely administered LPS is non-inferior to NC with routinely administered LPS.",[470,171],"Pregnancy Related",[472,177,473,322,474,475,199],"implantation rate","pregnancy rate","luteal phase support","live birth","2025-01-08",{"date":478,"type":39},"2025-01-09",{"date":480,"type":39},"2023-09-05",{"date":482,"type":21},"2026-09-30",{"name":45,"class":46},{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":491,"enrollmentInfo":492,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":47},"100500620","impact-of-a-previous-cs-on-the-ongoing-pregnancy-rate-in-single-euploid-frozen-embryo-transfer-et-100500620","NCT05798624","Impact of a Previous CS on the Ongoing Pregnancy Rate in Single Euploid Frozen Embryo Transfer (ET)","To Study the Impact of a Previous Cesarean Section (CS) With \u002F Without an Isthmocele on the Ongoing Pregnancy Rate in Single Euploid Frozen Embryo Transfer","Inclusion Criteria:\n\n\\- All participants undergoing a single euploid FET, independent of the endometrial preparation approach\n\nExclusion Criteria:\n\n* Intracavitary fluid during preparation for FET\n* Known anomaly of the uterus or the adnexae (e.g.: fibroids, polyps, hydrosalpinx, endometriosis, adenomyosis)\n* Embryo which was biopsied on day 7\n* Poor quality embryo which was transferred (Gardner criteria: AC \u002F BC \u002F CB, biopsied on day 6 and CC embryos from both, day 5 and day 6 biopsies, classified as \"poor\" quality embryos)\n* History of recurrent abortion\n* Antiphospholipid syndrome \u002F autoimmune diseases","42 Years",{"count":493,"type":21},1050,"As embryo ploidy is a crucial factor not only for implantation but also for maintenance of a pregnancy, the aim of this study is to evaluate the impact of the CS \u002F isthmocele on the ongoing pregnancy rates and the implantation site in single euploid frozen embryo transfer, independent of the endometrial preparation approach.",[138,496],"Implantation",[496,138,498,499],"Isthmocele","Cesarean section","2024-07-16",{"date":502,"type":39},"2024-07-17",{"date":504,"type":39},"2023-05-01",{"date":506,"type":21},"2025-07-30",{"name":45,"class":46},""]